Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib Long-term Extension Study
NCT01804686Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2013
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 29
01
Overview
A Phase 3 trial of ibrutinib in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), sponsored by Janssen Pharmaceutical. Started Sep 2013; status: active, not recruiting.
02
Drugs
ibrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)mantle cell lymphoma (MCL)follicular lymphoma (FL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT01804686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01804686.